Psyence Group Inc.
PSYGF
(Other OTC)

Recent

price

0.01

P/E

ratio

-0.02

div

yld

- -

ROIC.AI

Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.
Business
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.

Company News

  • Psyence Biomed Announces Closing of $2.0 Million Private Placement

  • Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

  • Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

  • Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

  • Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

  • Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

  • Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

  • Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

  • Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

  • Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

  • Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

  • Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

  • Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

  • Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

  • Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

  • Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

  • Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

  • Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

  • Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

  • Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones